Core Viewpoint - The company, Green Bamboo Bio-B (02480.HK), focuses on the research and development of vaccines and therapeutic biological agents, with its core product being the recombinant herpes zoster candidate vaccine LZ901, which is not yet commercialized and relies on government subsidies for revenue [1] Recent Events - The Biologics License Application (BLA) for LZ901 was accepted by the National Medical Products Administration in February 2025 and is currently under normal review, making the review results and subsequent commercialization process a focal point for the market [2] Project Progress - The company has increased its pipeline of preclinical products to six, including recombinant HSV-1 vaccine (for oral herpes) and recombinant HSV-2 vaccine (for genital herpes), with potential disclosures regarding clinical trial applications or progress in the future [3] Financial Performance - The company regularly publishes monthly reports on share changes, with the latest report for the period ending December 31, 2024, to be disclosed on January 7, 2026, which may reflect changes in shareholder structure. Financial data for 2024 shows R&D expenses of 135 million yuan and a pre-tax loss of 168 million yuan, narrowing by 32.5% year-on-year. Investors should pay attention to the full-year performance announcement for 2025 to assess operational improvements [4] Company Status - The latest ESG rating from Huazheng Index as of October 31, 2025, is BB, ranking 25th in the industry. Any adjustments to this rating may impact the attention of institutional investors [5]
绿竹生物-B核心产品LZ901审评获受理，2024年亏损同比收窄